Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Ambrx Biopharma Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19
   20-F20-F20-F
Revenues:  
    Reimbursements  1.90.42.8
    License Fees  3.511.02.3
    Research And Development Services  2.12.21.7
    Other    3.5
Total revenues  7.513.710.3
            Revenue growth   [+]-45.5%32.6% 
Cost of goods sold  0.00.00.0
Gross profit  7.513.710.3
            Gross margin  100.0%100.0%100.0%
Selling, general and administrative   [+]17.16.46.4
Research and development  54.820.426.4
Other operating expenses  0.00.00.0
EBITDA   [+]-62.3-11.2-20.4
            EBITDA margin  -835.3%-81.7%-198.0%
Depreciation  0.60.50.6
EBITA  -62.8-11.7-21.0
            EBITA margin  -842.7%-85.3%-203.9%
Amortization of intangibles  1.61.51.5
EBIT   [+]-64.4-13.1-22.5
            EBIT margin  -864.2%-95.9%-217.9%
Interest income   0.00.2
Other income (expense), net  -3.9-4.80.0
Pre-tax income  -68.3-17.8-22.3
Income taxes  0.00.00.0
            Tax rate    0.0%
Net income  -68.3-17.8-22.3
            Net margin  -916.0%-130.5%-216.4%
   
Basic EPS   [+]($0.48)($0.15)($0.16)
Diluted EPS   [+]($0.48)($0.15)($0.16)
   
Shares outstanding (basic)   [+]143.2115.7136.1
Shares outstanding (diluted)   [+]143.2115.7136.1
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy